• November 2025
  Towards the Functional Cure of HBV: Biomissile Announces Breakthrough Clinical Results for BM012 (HT-102) at AASLD 2025
  Read More
• July 2025
  Biomissile and Fudan University Announce Publication of Phase 2 Trial Results for BM219, a Novel Inhaled Bispecific UDAB-Based Antibody for Mild-to-Moderate COVID-19
  Read More
• March 2025
  "Biomissile’s Multispecific Antibodies Harness NK Cell Engagers" by Tamra Sami of BioWorld, Clarivate
  Read More
• September 2024
  The Prestigious Recognition of "Future Unicorn Enterprises of Jiangsu Province" in the Year 2024
  Read More
• September 2024
  Biomissile Wins the First Place Award at 2024 CHINABIO®’s “Startup Spotlight Pitch Competition” and RMB 500K Prize by the Forum Sponsor
  Read More
• May 2024
  Biomissile Named on the “2024 VBEF AWARDS-MOST INNOVATIVE AND CREATIVE PRODUCTS IN HEALTHCARE”
  Read More